GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives
International Journal of Molecular Sciences · 15.01.2023 · 24 (2) · 1703
DOI: 10.3390/ijms24021703 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 15.01.2023. Verfasst von Riccardo Nevola und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Medical and Surgical Sciences, Università Della Campania "Luigi Vanvitelli", I-80131 Naples, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptide-1 Receptor, Non-alcoholic Fatty Liver Disease, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 289-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
To date, non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease, affecting up to 70% of patients with diabetes. Currently, there are no specific drugs available for its treatment. Beyond their anti-hyperglycemic effect and the surprising role of cardio- and nephroprotection, GLP-1 receptor agonists (GLP-1 RAs) have shown a significant impact on body weight and clinical, biochemical and histological markers of fatty liver and fibrosis in patients with NAFLD. Therefore, GLP-1 RAs could be a weapon for the treatment of both diabetes mellitus and NAFLD. The aim of this review is to summarize the evidence currently available on the role of GLP-1 RAs in the treatment of NAFLD and to hypothesize potential future scenarios.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Advanced Medical and Surgical Sciences, Università Della Campania "Luigi Vanvitelli", I-80131 Naples, Italy.
ORCID-Profile: Riccardo Nevola, Raffaele Galiero, Luca Rinaldi, Raffaele Marfella, Ferdinando Carlo Sasso
Zitieren
APA
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. International Journal of Molecular Sciences, 24(2), 1703. https://doi.org/10.3390/ijms24021703
Vancouver
Nevola R, Epifani R, Imbriani S, Tortorella G, Aprea C, Galiero R, et al. GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. International Journal of Molecular Sciences. 2023;24(2):1703. doi:10.3390/ijms24021703
BibTeX
@article{Nevola2023,
author = {Nevola, Riccardo and Epifani, Raffaella and Imbriani, Simona and Tortorella, Giovanni and Aprea, Concetta and Galiero, Raffaele and Rinaldi, Luca and Marfella, Raffaele and Sasso, Ferdinando Carlo},
title = {GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {2},
pages = {1703},
doi = {10.3390/ijms24021703}
}
EUVIMED